主页
市场
图表与思路
Algo
新闻
商店
经纪商
下载
经济日历
交易信号
网页端
热图
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
REPL
#2262
Replimune Group, Inc. - Common Stock
8.6
9
USD
+86.08%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
+86.08%
每月变动
+265.13%
6个月变化
-13.10%
年变化
-6.46%
前一天收盘价
4.6
7
Open
8.6
9
最低价
8.6
9
High
8.6
9
交易量
104
市场
US Stock Market
医疗保健
REPL
展开完整图表
完整图表
Financials
概览
声明
统计
每季度
年度
利润表
资产负债表
现金流
值
2020
2021
2022
2023
2024
TTM
经营活动产生的现金
-61.39 M
-82.18 M
-128.05 M
-185.47 M
-192.25 M
-277.91 M
投资活动产生的现金
-188.78 M
-1.81 M
-142.5 M
97.2 M
-23.8 M
216.64 M
融资活动产生的现金
372.46 M
6.6 M
311.3 M
16.28 M
252.4 M
10.48 M
自由现金流
-63.78 M
-84.52 M
-130.32 M
-191.13 M
-198.94 M
-283.27 M
新闻
Biotech Investors Are Tuning Out the MAHA Chaos
What's Going On With Replimune Stock On Tuesday? - Replimune Group (NASDAQ:REPL)
Replimune stock collapses 64% following FDA rejection
Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More
美国股市上涨;截至收盘道琼斯工业平均指数上涨0.63%
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)
FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease